Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
In blow to Lula, Brazil Congress revives controversial environmental bill - 2Cannabis reclassification could 'open the floodgates' for research, scientists say
- 3Toddler diagnosed with cancer makes remarkable recovery after aggressive treatment
- 4The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic
- 54 Jeep Models: Dominating Execution and Flexibility for Each Experience
- From Amateur to Master: My Involvement in Photography
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- ‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
- Why Cannes Is the Ultimate New Year’s Eve Destination in the South of France’s Off-Season
- Ancient eggshells shed new light on crocodiles that hunted prey from trees
- 2024 Manual for Light Extravagance Room Feel: What's Moving
- Major railway disruptions persist as Germany braces for more snow
- Interstellar comet 3I/ATLAS will fly by Earth Friday. Here are the latest images
